Corneal and retinal angiogenesis are driven by vascular endothelial growth factor (VEGF) and are key events in corneal transplant rejection, trauma, age-related macular degeneration, and diabetic retinopathy. We propose to suppress VEGF using an intracellular, anti-angiogenic strategy relying on plasmids which express Flt23k intraceptors, recombinant subunits of Flt-1 (VEGF receptor 1) domains 2 and 3 coupled with KDEL at C-terminal which sequester VEGF within cells, in concert with a targeted nanoparticle delivery system. We previously demonstrated biodegradable, nontoxic, albumin nanoparticles containing plasmids expressing Flt-intraceptors sustained angioinhibition for up to 6 weeks. We will now advance nanoparticle delivery through conjugation with transferrin (to facilitate topical delivery) or with arginine-glycine-aspartic acid (RGD) oligopeptides (to home to neovascular tissues). Targeted delivery of anti-angiogenics to block VEGF intracellularly selectively in neovascular tissues is a significant unmet medical need as recent data indicate that long-term use of intravitreal ranibizumab (the widely used anti-VEGF Fab fragment, which binds VEGF extracellularly) is associated with a 30% risk of developing geographic atrophy within 2 years and over 50% risk at 7 years. We hypothesize that targeted expression of Flt23K """"""""intraceptors"""""""", will inhibit corneal transplant rejection and choroidal neovascularization, while mitigating development of fibrosis or atrophy.
Our specific aims are to determine whether: 1. Plasmids expressing intraceptors will inhibit angiogenesis and rejection of corneal transplants. We will test delivery using subconjunctival injections or topical delivery of nanoparticles designed to cross the corneal epithelium. 2. Targeted nanoparticles delivering plasmids expressing intraceptors can inhibit and regress choroidal neovascularization (CNV) in laser-induced and transgenic models. 3. Long-term nanoparticle expression of intraceptors affects tissue re-epithelialization in corneal transplant and tissue fibrosis or atrophy in CNV models.

Public Health Relevance

The project seeks to determine whether very small particles encapsulating a drug can block the development of vision-threatening new vessels (angiogenesis) at the cellular level in for the protection of corneal transplants and age-related macular degeneration (AMD). This study will demonstrate the potential of nanoparticles for long-term therapy;either as a topical drop (for corneal disease) or targeted intravenous injection (for AMD), resulting in new treatments which avoid the risks of current standard of care treatments (injections inside the eye) and improve outcomes for patients.

National Institute of Health (NIH)
National Eye Institute (NEI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (DPVS)
Program Officer
Mckie, George Ann
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Utah
Schools of Medicine
Salt Lake City
United States
Zip Code
Mukhtar, Sabrina; Ambati, Balamurali K (2018) Pediatric keratoconus: a review of the literature. Int Ophthalmol 38:2257-2266
Bowen, Randy C; Zhou, Andrew Xingyu; Bondalapati, Sailaja et al. (2018) Comparative analysis of the safety and efficacy of intracameral cefuroxime, moxifloxacin and vancomycin at the end of cataract surgery: a meta-analysis. Br J Ophthalmol 102:1268-1276
Singh, Malkit K; Ambati, Balamurali K; Crandall, Alan S (2017) New capsular tension segment with 2-point fixation for zonular weakness. J Cataract Refract Surg 43:590-592
Bondalapati, Sailaja; Ambati, Bala (2017) Intraocular foreign body removal: a novel technique using intraoperative imaging. Int Ophthalmol 37:749-752
Ambati, Balamurali (2017) Re: Schwartz et al.: Intracameral antibiotics and cataract surgery: endophthalmitis rates, cost, and stewardship (Ophthalmology. 2016;123:1411-1413). Ophthalmology 124:e42-e43
Lambert, Nathan G; ElShelmani, Hanan; Singh, Malkit K et al. (2016) Risk factors and biomarkers of age-related macular degeneration. Prog Retin Eye Res 54:64-102
Yasuma, Reo; Cicatiello, Valeria; Mizutani, Takeshi et al. (2016) Intravenous immune globulin suppresses angiogenesis in mice and humans. Signal Transduct Target Ther 1:
Bogdanovich, Sasha; Kim, Younghee; Mizutani, Takeshi et al. (2016) Human IgG1 antibodies suppress angiogenesis in a target-independent manner. Signal Transduct Target Ther 1:
Bosco, Alejandra; Romero, Cesar O; Breen, Kevin T et al. (2015) Neurodegeneration severity can be predicted from early microglia alterations monitored in vivo in a mouse model of chronic glaucoma. Dis Model Mech 8:443-55
Uehara, Hironori; Mamalis, Christina; McFadden, Molly et al. (2015) The reduction of serum soluble Flt-1 in patients with neovascular age-related macular degeneration. Am J Ophthalmol 159:92-100.e1-2

Showing the most recent 10 out of 33 publications